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S U M M A R Y
Objectives: There is scant qualitative research into the experiences of tuberculosis (TB) treatment in
urban risk groups with complex health and social needs in the UK. This study aimed to describe the social
context of adherence to treatment in marginalized groups attending a major TB centre in London.
Methods: A qualitative cross-sectional study was performed using semi-structured interviews with
patients receiving treatment for TB. Analytical frameworks aimed to reﬂect the role of broader social
structures in shaping individual health actions.
Results: There were 17 participants; the majority were homeless and had complex medical and social
needs, including drug and alcohol use or immigration problems affecting entitlement to social welfare.
Participants rarely actively chose not to take their medication, but described a number of social and
institutional barriers to adherence and their need for practical support. Many struggled with the physical
aspects of taking medication and the side effects. Participants receiving directly observed therapy (DOT)
reported both positive and negative experiences, reﬂecting the type of DOT provider and culture of the
organization.
Conclusions: There is a need for integrated care across drug, alcohol, HIV, and homeless services in order
to address the complex clinical co-morbidities and social needs that impact on the patient’s ability to
sustain a course of treatment.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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A recent cross-sectional survey of tuberculosis (TB) notiﬁcation
rates across the European Union (EU) reported that 15 out of
54 cities had notiﬁcation rates twice the national country rate, with
some cities experiencing rates three to four times the national
level.1 These included Birmingham and London (UK), Brussels
(Belgium), and Rotterdam (Netherlands). The authors attributed
the high rates of TB in major conurbations, in countries otherwise
classiﬁed as having a low incidence of disease, to the high
concentration of urban risk groups. This raises particular
challenges for a national TB control programme.* Corresponding author. Tel.: +44(0)20 7040 5843.
E-mail address: Gill.Craig.1@city.ac.uk (G.M. Craig).
http://dx.doi.org/10.1016/j.ijid.2015.01.007
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Cases of TB are over-represented in socially and economically
marginalized groups in high-income countries. In 2013 in the UK,
for example, 70% of the TB caseload came from the 40% most
deprived areas, and 44% of TB cases did not have employment.2
Groups that are affected by TB in the UK include migrants from
high TB endemic countries, homeless populations, prisoners,
people living with HIV/AIDs (PLWHA), and people who use drugs
(PWUD) and alcohol. These groups are at greater risk of TB than the
general population. They also comprise 38% of non-treatment
adherent cases, 44% of cases lost to follow-up, and 30% of cases
deemed highly infectious, and represent approximately 17% of the
London TB caseload.3 Approximately 10% of the national caseload
is characterized by at least one social risk factor associated with
non-adherence, including drug abuse, alcohol abuse, homeless-
ness, and imprisonment (3.2%, 3.9%, 3.3%, and 2.9%, respectively).2
Failure to adhere to a prescribed course of treatment can result in
the development of drug-resistant disease (which is more difﬁcultciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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increased risk of transmission.4
The World Health Organization (WHO) has endorsed the use of
supervised pill-taking (directly observed therapy, DOT) as the
standard of care to promote adherence, although this has not been
applied consistently in the UK context,3 with fewer than half of
eligible patients receiving DOT in 2013.2 This can either be
interpreted as a failure of services to upscale DOT, or that some
patients are perceived to be able to manage a course of treatment
without DOT.
Two reasons for non-adherence to medication have been
theorized: unintentional non-adherence (people intend to take
medication but fail to do so in the correct way), and intentional
non-adherence (people choose not to take medication).5 Criticism
of the adherence literature has been the dominance of psychologi-
cal approaches, which over-emphasize individual agency, particu-
larly in marginalized populations where choice and control are
most constrained.6,7
Gaining a better understanding of how wider contextual factors
impact on adherence is crucial if we aim to develop responsive
services that address both clinical and social needs. For example,
the results of two systematic, qualitative reviews concluded that
adherence to TB treatment was dependent on a range of complex
and interrelated factors, including both personal and structural
factors, the conﬁguration of health services, and the social and
economic context.8,9 The WHO adherence framework additionally
emphasizes therapy and condition-related factors (e.g., side effects
and co-morbidities).10
In this study we aimed to contextualize the experiences of our
participants within a ‘social determinants of health’ frame-
work11,12 in order to highlight how broader social structures
shape individual health actions that give rise to intentional and
unintentional non-adherence. We also aimed to identify examples
of ‘resilience strategies’ that our participants adopted to manage
their treatment.5 The study formed part of a wider service
development project conducted in London, UK, which aimed to
develop a social outreach model of care for marginalized groups
with TB and generate an evidence base for the need of a TB
caseworker in supporting clients with complex needs; this project
is reported elsewhere.13,14
2. Methods
2.1. Recruitment
Participants in this interview study were recruited from a major
TB centre characterized by a culturally diverse catchment area
including migrant and homeless populations, between 2003 and
2004. Interviewees were selected for inclusion based on a risk
assessment14 completed by nurses; this identiﬁed factors that
could complicate adherence to treatment (e.g., drug use, home-
lessness, and missed appointments) and the need for referral to a
caseworker for enhanced case management. Participants were
referred to the researcher by nurses or a case worker at different
stages of their treatment. Sampling was broadly purposive and
reﬂected a range of ‘critical case’ experiences typical of those
presenting with complex needs and the caseworker’s caseload.15,16
Participants were informed that the study was part of a new
initiative developing a social outreach model of support.17
Interviews lasted between 30 and 60 min and covered broad-
based themes about experiences of treatment. The majority of
interviews took place in the hospital outpatient clinic; three took
place on a hospital ward, one took place in a homeless hostel, and
one in a prison with the permission of managers. Clinic interpreters
were used in two cases. Interviews generally coincided with
patient appointments and they were offered a food voucher to thevalue of £5. Due to the difﬁculty of researching this group within a
clinical environment (e.g., lack of private spaces, frequent
interruptions) and because some patients experienced different
social risks impacting on adherence later in their treatment (e.g.,
people became homeless or their immigration status changed
affecting entitlements), participants were interviewed on more
than one occasion. All interviews were audio recorded and
transcribed verbatim, except for the two interviews involving
interpreters and one in the prison. Here notes were taken.
2.2. Analysis
The analysis was informed by a critical health psychology
perspective that understands illness behaviour within social,
political, and cultural contexts, which not only inﬂuence health
and illness, but healthcare organization and delivery.18 We
adopted a theoretical thematic analysis19 involving both deductive
(top down) and inductive (bottom up) coding and linking codes,
drawing on the WHO adherence framework (i.e., personal factors
such as resilience, social and economic contexts, therapy- and
condition-related factors, and healthcare systems). Segments of
relevant text relating to adherence and contextual information
were identiﬁed and compared across transcripts. Analytic memos
were used to aid analysis. Data analysis was managed using a
computer software programme designed speciﬁcally for the coding
and retrieval of qualitative data (QSR NUDIST*Vivo 10). Coding was
compared and corroborated between researchers, one with a social
science background and one with a background in nursing and
homelessness.
2.3. Ethical considerations and consent
This research was carried out within the guidelines of the
University College London Hospital Research Ethics Committee,
which approved the study. Written or verbal consent was obtained
(as agreed with the Ethics Committee). Participants were advised
that the interview did not form part of their clinical care. If the
participant became tired or agitated, the interview was terminated
and rescheduled. Where a participant became distressed or
disclosed distressing experiences, the researcher terminated the
interview and offered a referral to the caseworker.
3. Results and discussion
3.1. Participant characteristics and the wider context of adherence
Seventeen participants were interviewed: 16 with a conﬁrmed
diagnosis of TB and one with suspected TB. The majority of
interviewees were male (71%; 12/17). Just over half were born in
the UK (59%; 9/17); six of these participants described their
ethnicity as White British. The remainder were of Irish origin
(n = 2), Black British (n = 1), or Black African (n = 2); one woman
described herself as Jewish. Of those born outside the UK, two were
Ethiopian and three were Somali. The mean age of respondents was
44 years (range 18–67 years; n = 16) at the start of their initial
treatment. Table 1 provides further details, including co-morbid-
ities and drug resistance.
3.2. Income, housing, and employment
The majority of participants were homeless according to
statutory legislation. Five participants had complex immigration
cases affecting their entitlement to housing and welfare. Three
became unemployed due to illness and were therefore left without
an income. The remainder were in receipt of social welfare or a
voucher scheme (used in exchange for food in designated shops).
Table 1
Social characteristics of interviewees13
Interviewee ID Usual pattern of housinga Place of
birth
Criminal
justice
Drug
use
OST Alcohol HIV-positive Other self-reported
health conditions
Drug-resistant
TB
ID01 Hostel UK U PWID U U Epilepsy INH
ID02 NFA UK U U Epilepsy
ID03 Shared house (temporary) Ethiopia
ID04 Bedsit; hostel Nigeria U PWUD U Diabetes INH
ID05 NFA UK PWID U
ID06 NFA UK U PWID U U
ID07 B&B; staying with relatives
in their house
Somalia Hypertension, diabetes, ulcer
ID08 At risk as no recourse to
public funds due to
immigration status
Nigeria U Drug-induced diabetes
ID09 NFA UK U PWID U Hepatitis C
ID10 NFA; hostel Ethiopia
ID11 NFA; sometimes
stays at a friend’s house
UK U Stomach ulcers
ID12 B&B Somalia
ID13 NFA Ireland U Arthritis
ID14 Hostel UK U PWID U U U
ID15 Temporary bedsit UK U PWID U U Hepatitis
ID16 Hostel UK PWID U INH
ID17 B&B Somalia INH
OST, opioid substitution therapy (methadone); TB, tuberculosis; PWID, person who injects drugs; PWUD, person who uses drugs; INH, isoniazid; NFA, no ﬁxed abode usually
sleeping on streets; B&B, an individual room to sleep where breakfast is sometimes offered.
a Did not have one main place of residence but would alternate.
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income, including sex work, begging, stealing to obtain food or
drugs, reliance on food handouts, informal assistance from
relatives, casual labour, and community support.
3.3. Drug and alcohol use
Nine (53%) participants reported drug use including polydrug
use. Seven participants were receiving opioid substitution therapy
(OST; methadone maintenance) at the time of interview. PWUD
also reported consuming alcohol, but to different degrees. Three
other participants reported problematic alcohol use. Everyday
routines were dominated by drug and alcohol consumption, and
for people who injected drugs (PWID), measures to ﬁnance their
drug use and prevent drug withdrawal syndrome.
3.4. Experiences of violence and social exclusion
Many participants disclosed past experiences of violence,
torture, and physical and sexual abuse. Others spoke of lives
dominated by a cycle of crime, including youth offending, drug use,
and imprisonment. Their experiences were ﬁrmly embedded
within narratives of violence and exclusion,20 and in some cases
illustrated the cumulative effect of disadvantage impacting and
constraining behavioural choices.10,11
3.5. Support
A lack of social support from friends and family was a signiﬁcant
issue for many participants due to their migrant/refugee status, or
because they were estranged from their family. Few were able to
identify people who offered support on a regular basis. Some
family members were reported to provide ﬁnancial support, but
not emotional or practical aid. People who were homeless mostly
had other homeless people in their social network, which limited
the type of support available. One person reported increased
support from his family following a noticeable improvement in his
condition (ID12). Another received support from a close friend who
would ring him to remind him to take his medication (ID03). In
general, the participants were reliant on the TB clinic for support,or hostel workers who would remind patients to take their
medicines or accompany them to clinic appointments. However
this was not always consistent, as funding sources and lack of
training often precluded assistance with healthcare. One man
reported that hostel staff would not come to his room if he was too
ill to get up:
‘‘They don’t [check on you]. No. Because they say they are, it is
not a nursing home’’ (ID04).
When asked about the type of support needed, participants
responded with reference to material or practical assistance, such
as ﬁnding a job, housing, money to buy ‘good’ food, assistance with
shopping, coming off drugs, and someone to talk to.
3.6. Disclosure and stigma
An older Somali refugee described how she hid her diagnosis
and her TB medication from the relatives she lived with,
administering them in secret. Her fear of disclosure related to
the threat of eviction and rejection by the wider Somali
community, resulting in a loss of material and social support:
‘‘I keep medication in a secret place and take medication at a
secret time. The other illness (diabetes) they (relatives) know
about it and accept it. The ﬁrst thing I will lose is my
accommodation and the relationship. My situation could then
be communicated to other Somalians’’ (ID07).
Scambler21 suggests the fear of negative reactions (felt stigma)
can be more detrimental psychologically than the actual experi-
ence of discrimination (enacted stigma) because of the effort
people expend when trying to conceal their condition. According to
this theory, people become so adept at concealment as a ﬁrst
choice strategy that examples of enacted stigma are rare. Moreover
the adverse effects of stigma may have a greater impact on women
because of their (gendered) social location.22 Some participants
reported that the disease was used as an excuse to shun or evict a
person because of dislike (ID03) rather than stigma. Others noted
social distancing (ID01), sympathy (ID05), indifference (ID02), and
acceptance where family were able to witness the beneﬁcial effects
of treatment (ID12).
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3.7.1. Hospital practice on methadone maintenance, drugs, and
alcohol consumption
Although there are guidelines on OST to stabilize PWID while
in hospital,23 there was a perception that, along with other
drugs obtained illicitly (e.g., valium/diazepam), these were
under-prescribed. The frequency of dosing, sometimes with
long intervals due to delays in administering methadone, was
such that some patients experienced withdrawal syndrome.24
This was frightening where they felt they had little control,
illustrating the psychosocial aspects of withdrawal. Physicians
may fear the consequences of over-prescribing methadone and
the conﬂicts experienced between meeting the needs of
patients and adhering to prescribing protocols, with the
potential for an impact on the therapeutic relationship having
been documented.25
As some hospital wards operated a zero tolerance policy in
relation to drug and alcohol use, participants reported leaving the
hospital to obtain drugs to cope. Some reported that staff,
adopting a lenient approach, turned a blind eye to alcohol use off
premises provided patients returned to the ward; a ‘compromise’
to encourage adherence to treatment plans. Consultants some-
times refused to treat patients unless they agreed to modify their
behaviour. In extreme cases, patients were coerced into
complying with treatment in order to avoid compulsory
detention.
3.7.2. Hospitalization as a safety net or welcome break
In contrast to those who experienced drug withdrawal while in
hospital, one homeless man was more able to tolerate the demands
of hospitalization, which he viewed as a welcome break from the
cold and months of homelessness living on the street: ‘‘it was like a
bit of a holiday’’ (ID05). As a methadone user with occasional
heroin use, his daily routines were less dominated by drug use and
withdrawal.
In some cases, interviewees experienced lengthy periods of
hospitalization for social reasons in addition to medical need. One
young woman spent several months in hospital due to homeless-
ness and a history of sexual exploitation (ID10). Despite having
lived in the UK since a child, her immigration status precluded any
recourse to public funds, rendering her destitute. The doctors
decided to delay discharge from the hospital because she was very
young and vulnerable. She remained an in-patient for several
months until the Social Services accepted they had a duty of care
and provided accommodation allowing a safe-discharge and stable
environment for her to complete her treatment.
3.8. Directly observed therapy (DOT)
Those patients receiving medicines through DOT (n = 9) spoke
of the beneﬁts in terms of contact with ‘normal people’ and ‘female
company’ (for some homeless men), support from staff, and the
structure the clinic visits afforded:
‘‘. . .the day I’m not going to the clinic it’s difﬁcult to get up. It’s
my day out’’ (ID01).
For PWID, DOT was provided at a number of locations including
the Drug Dependency Unit (DDU) or pharmacist in conjunction
with methadone, the hostel via outreach workers, or the TB clinic.
However DOT was not always successful even where the location
or provider changed. PWID did not always attend the DDU, either
because of the distance they had to travel, or because they had used
or intended to obtain drugs. The monitoring of pill swallowing also
varied across different healthcare locations; whereas some staff
made distinct efforts to check that all pills had been swallowed,particularly where methadone was dispensed, others supervised at
arm’s length ‘‘out of the corner of their eye’’. There was however
evidence of resentment where DOT was administered in an
authoritarian atmosphere:
‘‘I hated it. Um, (pause) I felt that, I was threatened, you know,
it’s like, if you didn’t take this, then you couldn’t have that, I felt
like I was at school. And, in the end I just wanted to say: **** the
lot of you. Because I couldn’t take the TB pills you know, my
body did not want the pills any more, but, my body still needed
the methadone’’ (ID15).
3.9. Personal factors – experience of medication and resilience
strategies
For those participants not receiving DOT, a dominant theme
was the way treatment regimens impacted on everyday routines,
compounded by the number and size of tablets and frequency of
dosing.26 A healthcare worker taking medication for both HIV
and TB spoke of the day dominated by pills and the difﬁculty of
taking the prescribed regimen when trying to maintain daily
routines such as shopping. She took nine pills in the morning,
seven at lunch time, three in the afternoon, and seven at night.
The only way to manage her regimen was to skip the afternoon
dose:
‘‘I’ve never missed my morning drugs and my night drugs. But
my afternoon drugs: yes’’ (ID08).
This example illustrates the limitations of pill organizers when
faced with the demands of the schedule of dosing. It was not her
memory that failed her; rather, the lack of practical support with
her daily activities. Others appeared more able to incorporate
tablets into their daily routines where pill-taking already formed
part of their everyday lives (e.g., pills for hypertension).
The difﬁculty of combining medication with an itinerant
lifestyle and the storage of medicines was a major problem. One
homeless man had his bag stolen (ID05) and others reported
difﬁculties carrying medicines with them such that where they
had stored their medication was not where they ended up
sleeping. Participants reported running out of medicines. The
requirement to take medicines on an empty stomach, 1 h before
food, when some patients had little control over the availability of
food in terms of supply or affordability, was also a factor,
particularly where they depended on ‘handouts’ provided by
charities. Here food was prioritized over pill-taking. Others
radically changed their eating and sleeping patterns in order to
take medication.27 One participant ensured that she did not eat
anything after 3 a.m. in order to take her morning medication on
an empty stomach. Another reported that he missed his
medicines if looking for money to buy drugs or if taking heroin
instead of methadone.
Those with more routinized and stable lifestyles were able to
manage their medicines and devised resilience strategies by
creating reminders,5 such as setting an alarm clock, or a memory
aid in the form of a chart to record pill-taking. Others attempted to
cut up or crush tablets (although not medically recommended) or
consumed tablets with nutrient drinks to avoid feeling sick.
Modifying regimens rather than take medicines as prescribed has
been described as ‘purposeful non-adherence.’27
The quality of reminder cues also varied and some were more
vulnerable to failure, as in the example of the homeless man who
struggled to take his medication due to a combination of poor
memory, tiredness, problems swallowing, and alcohol use (ID02).
He developed a routine that involved leaving his tablets in a place
near to where he slept, only to awake to ﬁnd someone had moved
them.
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medicines
Although much emphasis is placed on adherence to treatment,
the adverse effects of therapy receive less attention.27 Some
reported feeling nausea or vomiting following taking their
medicines (‘‘Most day I vomit after taking my medication’’
(ID08)), which may be due to the number of tablets, particularly
where administered through three-times weekly DOT (ID14).
Numbness and dizziness (D08) has also been reported in patients
taking antiretrovirals.27 Others described what appeared to be
adverse drug reactions that caused them to interrupt their
treatment. The side effects of isoniazid also include nausea,
vomiting, and numbness. Some PWUD found it difﬁcult to
distinguish between the symptoms of TB, other co-morbidities,
and the adverse effects of medication:
‘‘Feel better but can’t remember feeling bad because so
wrapped up in drugs and alcohol. Walking from the hostel to
get methadone, I was sweating like mad. Can’t remember if it
was TB drugs, drink or combination’’ (ID01).
Conversely another patient was able to attribute the cause of his
symptoms speciﬁcally to TB medication because of withdrawal
syndrome, reﬂecting the way rifampicin reduces the effect of
methadone.28
‘‘The tablet’s, actually, [have] halved, the dosage of methadone.
So instead of me being on a hundred and twenty ﬁve, I’m only
getting sixty two and a half per cent in my body, because the pills
are wiping out, the other sixty two and a half per cent’’ (ID14).
His methadone was later increased to compensate. Alcohol
consumption resulting in vomiting, diarrhoea, or blackouts was
also given as a reason for not taking medicines (ID16).
4. Conclusions
Research has theorized two reasons for non-adherence:
intentional and non-intentional. The results of this study have
highlighted the structural and institutional contexts impacting on
adherence to treatment.29 Drug and alcohol use was clearly a
complicating factor, as was homelessness, but other factors
included the culture of services (e.g., perceived to be authoritarian
or punitive); institutional policies (e.g., methadone-prescribing
practices and zero tolerance on drug and alcohol consumption
resulting in withdrawal syndrome, patients leaving the hospital);
lack of effective partnership working with homeless organizations
or ﬁnancial restrictions placed on those organizations by funders
impacting on their ability to support patients; requirements to
take medication in prescribed ways geared towards those with
routinized lifestyles (e.g., in relation to mealtimes); and the
adverse effects of therapy coupled with complex co-morbidities
(resulting in nausea and vomiting). Those receiving DOT reported
both positive and negative experiences relating to the type of DOT
provider and culture of the organization.
Participants appeared more able to sustain a course of
treatment where their environment was stable and where they
received support through friends, family, community services, or a
case worker, which played an important role. Practical support was
valued and has been found to support adherence in other
conditions.30 Some participants showed evidence of quite sophis-
ticated resilience strategies in managing their medication.
A Cochrane review of research to promote adherence more
generally31 identiﬁed 21 strategies that, with little exception (e.g.,
group meetings), focused on interventions at the individual patient
level. In our study, however, people rarely actively ‘chose’ not totake their medication. Rather adherence to treatment involved a
complex interplay of factors involving their social location, co-
morbidities, and service policy and delivery. Interventions that
target individual coping skills are therefore unlikely to meet with
success in marginalized populations, such as those described here,
in the absence of measures to address the ‘risk environments’32
(e.g., homelessness) that render people vulnerable to both TB
disease and non-adherence to treatment.
Rather than view non-adherence as individual failure, a more
productive approach would be for services to collectively share the
responsibility for treatment adherence, and any associated risks,
through the co-creation of localized, inter-sectoral, collaborative
care pathways that integrate drug, alcohol, and homeless services
and that are able to address both clinical and social risks.17,33 This
will require smarter approaches to commissioning joint health and
social care services, with implications for resourcing and
workforce development.
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